Amicus Therapeutics, Inc. (FOLD) Social Stream
AMICUS THERAPEUTICS INC (FOLD) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering FOLD.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 11 | $29 | $12 | $18.333 | $11.2 | 63.69% |
| 2021-11-15 | 10 | $29 | $12 | $18.444 | $11.2 | 64.68% |
| 2021-11-23 | 10 | $29 | $12 | $18.555 | $11.2 | 65.67% |
| 2022-01-13 | 9 | $29 | $12 | $17.375 | $11.2 | 55.13% |
| 2022-01-17 | 9 | $29 | $15 | $17.875 | $11.2 | 59.6% |
| 2022-01-26 | 9 | $29 | $15 | $17.5 | $11.2 | 56.25% |
| 2022-02-25 | 9 | $29 | $14 | $17 | $11.2 | 51.79% |
| 2022-04-20 | 9 | $20 | $14 | $15.5 | $11.2 | 38.39% |
| 2022-05-10 | 10 | $20 | $11 | $15 | $11.2 | 33.93% |
| 2022-05-12 | 10 | $20 | $11 | $15.222 | $11.2 | 35.91% |
| 2022-08-05 | 7 | $20 | $11 | $15.285 | $11.2 | 36.47% |
| 2022-08-13 | 7 | $20 | $11 | $15.142 | $11.2 | 35.2% |
| 2022-10-19 | 8 | $20 | $11 | $15 | $11.2 | 33.93% |
| 2022-11-07 | 8 | $20 | $11 | $15.125 | $11.2 | 35.04% |
| 2022-11-15 | 8 | $20 | $11 | $15.428 | $11.2 | 37.75% |
| 2023-01-16 | 8 | $20 | $11 | $15.375 | $11.2 | 37.28% |
| 2023-02-08 | 8 | $20 | $11 | $15.875 | $11.2 | 41.74% |
| 2023-03-03 | 9 | $20 | $11 | $16.111 | $11.2 | 43.85% |
The Trend in the Analyst Price Target
Over the past 16 months, FOLD's average price target has gone down $2.22.
Over the past 45 weeks, FOLD's average upside potential has been 52.07%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-04-20 | 9 | 20 | 14 | 15.500 | 8.26 | 87.65% |
| 2022-09-17 | 8 | 20 | 11 | 15.000 | 10.62 | 41.24% |
| 2023-01-10 | 8 | 20 | 11 | 15.375 | 11.45 | 34.28% |
| 2023-01-16 | 8 | 20 | 11 | 15.375 | 12.83 | 19.84% |
| 2023-01-16 | 8 | 20 | 11 | 15.875 | 12.83 | 23.73% |
FOLD Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.44 | 7 | 0 | 2 | 0 | 0 | 9 |
The Trend in the Broker Recommendations
Over the past 43 weeks, FOLD's average broker recommendation rating worsened by 0.04.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, AMICUS THERAPEUTICS INC's average analyst price target is higher than 459.61% of them.
- In terms of how AMICUS THERAPEUTICS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -1597.83% of that group.
- In terms of how AMICUS THERAPEUTICS INC fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is higher than 533.51% of that group.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, AMICUS THERAPEUTICS INC's number of analysts covering the stock is higher than 1556.63% of them.
In the Pharmaceutical Products industry, ENTA, MDGL, and MGNX are the three stocks most similar to AMICUS THERAPEUTICS INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is FOLD a Buy, Hold or Sell? See the POWR Ratings now!